AJMC® in the Press, October 2, 2026

The article, “Health System Pharmacies Keep Patients on GLP-1 Therapy,” published on AJMC.com, the website of The American Journal of Managed Care^® (AJMC^®), reported that patients getting injectable glucagon-like peptide-1 (GLP-1) therapy through integrated health-system specialty pharmacies stayed on treatment longer and started it faster than is typical in real-world practice, based on 2 posters from Shields Health Solutions and partner health systems. At NYU Langone, 115 of 2943 patients (3.9%) discontinued within the first year, and in the second poster, the median time from prescription receipt to first dispense was 5 days.

Becker's Hospital Review’s “Health system pharmacy keeps 96% of GLP-1 patients on therapy” cited AJMC for the 3.9% first-year discontinuation rate among 2943 NYU Langone patients, along with the pharmacist onboarding and follow-up model behind it and the agent-specific discontinuation rates, including the small liraglutide and dulaglutide groups. Drawing further on AJMC's coverage, Becker’s highlights the second analysis of 1707 adults, citing the 5-day median time to first fill, the 95% prior authorization rate, and the $24.98 median out-of-pocket cost, before closing with the studies’ limitations.